News & Updates
Filter by Specialty:
RNAi agent RG6346 shows promise for treatment of chronic HBV infection
A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.
RNAi agent RG6346 shows promise for treatment of chronic HBV infection
17 Nov 2023
Antiviral therapy safe, effective in children with immune-tolerant HBV infection
Treatment with antiviral therapy is beneficial and generally tolerated in children with chronic hepatitis B virus (HBV) infection in the immune-tolerant stage, according to the results of a systematic review and meta-analysis.
Antiviral therapy safe, effective in children with immune-tolerant HBV infection
28 Oct 2023
Canagliflozin holds promise against MAFLD in T2D patients
Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.
Canagliflozin holds promise against MAFLD in T2D patients
27 Oct 2023
Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients
Treatment with the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide results in a greater decrease in liver fat content (LFC) relative to the GLP-1 receptor agonist semaglutide in patients with nonalcoholic fatty liver disease (NAFLD), results of a phase IIa trial have shown.
Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients
03 Oct 2023
Response to nucleos(t)ide analogues for hepatitis B higher among men vs women
Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.